Pharsight

Aliqopa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7511041 BAYER HEALTHCARE Fused azole-pyrimidine derivatives
May, 2024

(a month from now)

USRE46856 BAYER HEALTHCARE Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
Oct, 2029

(5 years from now)

US10383876 BAYER HEALTHCARE Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
Mar, 2032

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9636344 BAYER HEALTHCARE Substituted 2,3-dihydroimidazo[1,2-C]quinazoline salts
Mar, 2032

(8 years from now)

Aliqopa is owned by Bayer Healthcare.

Aliqopa contains Copanlisib Dihydrochloride.

Aliqopa has a total of 4 drug patents out of which 0 drug patents have expired.

Aliqopa was authorised for market use on 14 September, 2017.

Aliqopa is available in powder;intravenous dosage forms.

Aliqopa can be used as treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies.

The generics of Aliqopa are possible to be released after 29 March, 2032.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 14, 2024

Drugs and Companies using COPANLISIB DIHYDROCHLORIDE ingredient

Market Authorisation Date: 14 September, 2017

Treatment: Treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

ALIQOPA family patents

Family Patents